Sorafenib in Treating Patients With Relapsed or Refractory Multiple Myeloma
NCT00253578
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
40
Enrollment
NIH
Sponsor class
Conditions
Refractory Multiple Myeloma
Interventions
DRUG:
sorafenib tosylate
OTHER:
laboratory biomarker analysis
Sponsor
National Cancer Institute (NCI)